Cancer immunology research, Vol. 7, Issue 2, Pages 174-182, 2019

PMID: 30679156

T-cell recognition of cancer neoantigens is important for effective immune-checkpoint blockade therapy, and an increasing interest exists in developing personalized tumor neoantigen vaccines. Previous studies utilizing RNA and long-peptide neoantigen vaccines in preclinical and early-phase clinical studies have shown immune responses predominantly driven by MHC class II CD4(+) T cells.

Read More

  https://www.ncbi.nlm.nih.gov/pubmed/30679156